Valuation: Rigel Pharmaceuticals, Inc.

Market Cap 838M 756M 698M 631M 1.19B 78.63B 1.22B 8.37B 3.33B 42.11B 3.15B 3.08B 134B P/E 2026 *
15.1x
P/E 2027 * 11.7x
Enterprise Value 838M 756M 698M 631M 1.19B 78.63B 1.22B 8.37B 3.33B 42.11B 3.15B 3.08B 134B EV / Sales 2026 *
2.75x
EV / Sales 2027 * 2.29x
Free-Float
96.67%
Yield 2026 *
-
Yield 2027 * -
1 day+1.39%
1 week-13.20%
Current month-13.23%
1 month-9.29%
3 months+5.95%
6 months+69.92%
Current year+3.95%
1 week 37.6
Extreme 37.6
44.63
1 month 37.6
Extreme 37.6
52.6
Current year 24.95
Extreme 24.95
52.6
1 year 24.95
Extreme 24.95
52.6
3 years 7.48
Extreme 7.4843
52.6
5 years 6.4
Extreme 6.4
52.6
10 years 6.4
Extreme 6.4
55
Manager TitleAgeSince
Chief Executive Officer 65 21/11/2014
Director of Finance/CFO 63 29/05/2018
Compliance Officer 58 01/12/2022
Director TitleAgeSince
Director/Board Member 71 01/03/1997
Director/Board Member 65 21/11/2014
Chairman 67 01/05/2022
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Exercice

Chief Financial Officer

9,200 0.0493%
1/9/26 Tax

Compliance Officer

-877 0.0047%
1/9/26 Tax

Chief Executive Officer

-2,424 0.0130%
Change 5-day change 1-year change 3-year change Capi.($)
+1.39%-13.20%+17.31%+444.32% 827M
+0.35%+1.36%+45.38%+140.47% 1,276B
-0.13%+1.48%+44.67%+90.43% 676B
+0.37%+0.05%+31.00%+112.84% 519B
+0.02%+1.52%+39.21%+69.76% 388B
-0.59%-2.11%+61.83%+45.16% 365B
-1.29%-1.13%+27.54%+58.29% 307B
+0.09%-0.91%+3.19%+37.72% 287B
+0.62%-2.17%+38.31%+75.12% 252B
-0.67%-2.72%+38.49%+123.56% 212B
Average +0.17%-1.01%+34.69%+119.77% 428B
Weighted average by Cap. +0.47%+0.55%+39.50%+97.29%

Financials

2026 *2027 *
Net sales 305M 275M 254M 230M 435M 28.64B 446M 3.05B 1.21B 15.34B 1.15B 1.12B 48.81B 366M 329M 304M 275M 521M 34.28B 533M 3.65B 1.45B 18.36B 1.37B 1.34B 58.43B
Net income 58.49M 52.71M 48.7M 44.03M 83.29M 5.49B 85.35M 584M 233M 2.94B 219M 215M 9.35B 73.55M 66.29M 61.24M 55.36M 105M 6.9B 107M 734M 293M 3.69B 276M 270M 11.76B
Net Debt - -
Projected Income Statement - Annual - Rigel Pharmaceuticals, Inc.
Logo Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing therapies for patients with hematologic disorders and cancer. It focuses on products that address signaling pathways that are critical to disease mechanisms. Its products include TAVALISSE, REZLIDHIA, and GAVRETO. TAVALISSE is an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. REZLIDHIA is used for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation. GAVRETO is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions. It is used for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.
Employees
173
Date Price Change Volume
11/11/26 USD 44.52 +1.39% 140,664
10/11/26 USD 43.91 +4.42% 249,588
09/11/26 USD 42.05 +6.05% 310,277
06/11/26 USD 39.65 -13.26% 759,188
05/11/26 USD 45.71 -10.88% 551,002
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Rigel Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
44.52USD
Average target price
59.25USD
Spread / Average Target
+33.09%
  1. Stock Market
  2. Stocks
  3. RIGL Stock